Opdivo Injectable for Mesothelioma: 5-Minute Treatment Replaces Hour-Long Infusions

The FDA approved a subcutaneous formulation of nivolumab (Opdivo) in December 2024 that takes 3 to 5 minutes to administer — replacing the 30- to 60-minute intravenous infusions that mesothelioma patients previously required at every treatment visit. For the approximately 2,500 to 3,000 Americans diagnosed with mesothelioma each year, this shift represents a meaningful reduction in the time and logistical burden of receiving the checkpoint immunotherapy combination that has become the standard of care for unresectable pleural mesothelioma.

What Are the Key Facts About the New Opdivo Injection for Mesothelioma?

• The FDA approved subcutaneous nivolumab (Opdivo SC) in December 2024 for all solid tumor indications where IV nivolumab was previously approved — including unresectable malignant pleural mesothelioma
• The subcutaneous formulation delivers 600 mg nivolumab combined with recombinant human hyaluronidase (rHuPH20), which temporarily increases skin permeability to allow rapid absorption of the drug
• Administration takes 3 to 5 minutes via injection into the abdomen or thigh, compared to 30 to 60 minutes for IV infusion
• Clinical pharmacokinetic studies demonstrated equivalent drug exposure between subcutaneous and intravenous formulations — the drug reaches the same blood concentrations and achieves the same efficacy outcomes
• Nivolumab plus ipilimumab was first approved for unresectable malignant pleural mesothelioma in October 2020 based on the CheckMate 743 phase 3 trial
• CheckMate 743 enrolled 605 patients and showed 18.1-month median overall survival with immunotherapy versus 14.1 months with platinum-pemetrexed chemotherapy
• Two-year overall survival was 41% with nivolumab plus ipilimumab versus 27% with chemotherapy
• ASCO's 2025 updated mesothelioma guidelines designate dual checkpoint immunotherapy as the standard first-line treatment for unresectable pleural mesothelioma
• The subcutaneous formulation may cause mild local injection site reactions not seen with IV, but otherwise carries an equivalent side effect profile to IV nivolumab
• For patients receiving nivolumab every four weeks, the 5-minute injection can reduce cumulative annual clinic chair time by 6 to 12 hours compared to IV infusions

Why Does the Route of Administration Matter for Mesothelioma Patients?

Mesothelioma patients receiving first-line immunotherapy typically remain on nivolumab for as long as the treatment is effective and tolerable — often one to two years or longer for responding patients. Over the course of this treatment, the difference between a 5-minute subcutaneous injection and a 60-minute IV infusion compounds into significant time savings and reduced logistical burden.

A patient receiving nivolumab every four weeks over 24 months makes approximately 26 treatment visits. With IV infusions, each visit requires arriving early for blood draws, waiting for pharmacy preparation, sitting in an infusion chair for 30 to 60 minutes, and completing post-infusion observation. A single day at the cancer center for IV Opdivo can consume three to five hours of the patient's time including travel, check-in, infusion, and monitoring. With subcutaneous injection, the time spent on the actual drug administration shrinks to minutes.

The Understanding Your Diagnosis resource at WikiMesothelioma provides context on how mesothelioma staging and cell type influence treatment selection, including when immunotherapy is the preferred first-line approach over surgery or chemotherapy.

"I've spent twenty years in the pharmaceutical industry and eighteen years working with mesothelioma patients, and I can tell you that reducing the burden of treatment isn't a minor quality-of-life improvement — it's clinically significant. When patients are exhausted and dealing with side effects, the difference between a two-hour infusion day and a thirty-minute clinic visit can determine whether they stay on therapy." — David Foster, Executive Director of Client Services, Danziger & De Llano

For patients with difficult venous access — a common issue among older patients and those who have received multiple lines of therapy — IV infusions require placement of a central venous catheter or port, which introduces its own risks including infection and thrombosis. Subcutaneous injection eliminates the need for intravenous access entirely, removing this burden for patients who are not receiving other IV-administered treatments simultaneously.

How Does the Subcutaneous Formulation Work Differently From IV Nivolumab?

Intravenous nivolumab enters the bloodstream directly, achieving peak plasma concentration within 1 to 4 hours after infusion. Subcutaneous administration delivers the drug into the fat layer beneath the skin, where it must pass through subcutaneous tissue and lymphatic channels before reaching systemic circulation — a process that takes longer than direct IV delivery but ultimately achieves equivalent drug exposure over the dosing interval.

The key to making subcutaneous delivery of a large protein molecule like nivolumab feasible is recombinant human hyaluronidase (rHuPH20), an enzyme that temporarily degrades hyaluronan — a component of the extracellular matrix in subcutaneous tissue that normally limits how much fluid the tissue can absorb. By transiently increasing tissue permeability, rHuPH20 allows the 600 mg nivolumab dose to be absorbed rapidly from the injection site despite the large volume involved.

Phase 3 pharmacokinetic studies confirmed that the subcutaneous formulation achieves non-inferior drug exposure to IV — meeting the pre-specified statistical threshold that drug levels are equivalent enough to produce the same therapeutic outcomes. The FDA evaluated this equivalence data as the basis for approving the subcutaneous formulation across all tumor types where IV nivolumab had existing approval.

What Did the CheckMate 743 Trial Show About Opdivo for Mesothelioma?

CheckMate 743 was a randomized, open-label phase 3 clinical trial conducted across 103 sites in 21 countries. It enrolled 605 patients with histologically confirmed, previously untreated unresectable malignant pleural mesothelioma — the most common form of the disease, arising from the lining of the lungs. Patients were randomized to receive either nivolumab (3 mg/kg every two weeks) plus ipilimumab (1 mg/kg every six weeks) or standard platinum-pemetrexed chemotherapy.

The primary endpoint was overall survival in the total population regardless of PD-L1 expression or histologic subtype. The results were striking: the nivolumab plus ipilimumab combination produced a median overall survival of 18.1 months compared to 14.1 months for chemotherapy — a statistically significant improvement representing a 26% reduction in the risk of death. At two years, 41% of patients receiving immunotherapy were alive compared to 27% of those who received chemotherapy.

Particularly notable was the benefit in non-epithelioid histology (sarcomatoid and biphasic mesothelioma), which historically responds poorly to chemotherapy. In this subgroup, nivolumab plus ipilimumab produced a median overall survival of 18.1 months versus 8.8 months with chemotherapy — a finding that reshaped the treatment approach for these aggressive mesothelioma cell types. As documented in the Mesothelioma Quick Facts at WikiMesothelioma, cell type is a primary determinant of prognosis and treatment response in mesothelioma.

"What CheckMate 743 proved was that immunotherapy doesn't just match chemotherapy for mesothelioma — it outperforms it, particularly for the sarcomatoid patients who used to have almost no good options. And now with the subcutaneous formulation, we're making it easier for patients to stay on the treatment that's keeping them alive longer." — David Foster, Executive Director of Client Services, Danziger & De Llano

Based on CheckMate 743, the FDA approved nivolumab plus ipilimumab as the first new first-line treatment for unresectable pleural mesothelioma in more than 15 years. The combination is now one of the most important therapeutic advances in the history of mesothelioma treatment.

What Does the 2025 ASCO Guidelines Update Mean for Mesothelioma Patients?

ASCO — the American Society of Clinical Oncology — periodically updates its evidence-based clinical practice guidelines to reflect new trial data and emerging standards of care. The 2025 update to ASCO's mesothelioma treatment guidelines formally designates nivolumab plus ipilimumab as the standard first-line treatment for patients with unresectable malignant pleural mesothelioma who are not candidates for curative-intent surgery.

This designation matters practically for several reasons. Insurance coverage decisions frequently use ASCO guidelines as reference documents — when ASCO names a regimen as standard of care, coverage denial becomes harder to justify. Oncologists at community hospitals and cancer centers who may see mesothelioma infrequently now have a clear, authoritative reference supporting the immunotherapy combination over the previous default of chemotherapy. And patients themselves can cite the ASCO standard when advocating with their oncologist or insurer for access to the preferred treatment.

The guidelines update also acknowledges the broader landscape of checkpoint inhibitor research in mesothelioma, including ongoing trials evaluating combinations of immunotherapy with chemotherapy, maintenance immunotherapy following surgical resection, and novel immunotherapy agents. The designation of nivolumab plus ipilimumab as the current standard does not preclude enrollment in clinical trials testing potentially superior regimens.

What Are the Side Effects of Opdivo for Mesothelioma Patients?

Nivolumab and ipilimumab are both checkpoint inhibitors — drugs that block proteins that normally restrain immune cell activity. By removing these restraints, they allow T cells to attack cancer cells more aggressively. The same mechanism that creates therapeutic benefit can also cause the immune system to attack normal tissues, producing immune-related adverse events (irAEs) that are distinct from the toxicities of chemotherapy.

Common immune-related adverse events associated with nivolumab plus ipilimumab in CheckMate 743 included fatigue (approximately 43% of patients), rash (29%), diarrhea (25%), and elevated liver enzymes (21%). Grade 3 or 4 (severe) immune-related toxicities occurred in approximately 30% of patients receiving the combination — comparable to rates seen in other CheckMate trials and generally manageable with corticosteroids and treatment interruption.

Endocrine toxicities including hypothyroidism, hypophysitis (pituitary inflammation), and adrenal insufficiency occur in a subset of patients and often require ongoing hormone replacement therapy. These conditions are typically permanent once established but manageable with standard replacement regimens.

Pneumonitis (lung inflammation) is a potentially serious immune-related toxicity in mesothelioma patients, who already have compromised pulmonary function. Symptoms including new or worsening cough, shortness of breath, and fever should be reported promptly. High-grade pneumonitis may require permanent discontinuation of immunotherapy and intensive steroid treatment.

Injection site reactions specific to subcutaneous administration include local erythema, swelling, and tenderness at the injection site. These reactions are generally mild and transient, resolving within one to two days without treatment in most cases. Unlike infusion reactions associated with IV administration — which can occasionally be severe and require emergency intervention — subcutaneous injection site reactions are localized and predictable.

"Patients always ask me if the side effects are worth it. I tell them that checkpoint inhibitor side effects are different from chemotherapy side effects — they're largely immune system overreactions that we can treat effectively with steroids. And the survival data from CheckMate 743 shows that for mesothelioma, this treatment is keeping people alive significantly longer. That's a trade-off most patients are willing to make." — David Foster, Executive Director of Client Services, Danziger & De Llano

How Does Opdivo Fit Into the Broader Landscape of Mesothelioma Treatments?

Nivolumab plus ipilimumab is the preferred first-line regimen for patients with unresectable pleural mesothelioma who are appropriate candidates for immunotherapy. However, not all mesothelioma patients receive first-line immunotherapy, and treatment decisions are individualized based on performance status, histologic subtype, comorbidities, and patient goals.

Patients with resectable disease — typically Stage I or II epithelioid mesothelioma in high-volume surgical centers — may be candidates for cytoreductive surgery followed by adjuvant therapy. The role of perioperative immunotherapy in this setting is being actively evaluated in clinical trials following promising early data from institutions including Johns Hopkins.

Platinum-pemetrexed chemotherapy remains an option for patients who cannot tolerate immunotherapy, including those with severe autoimmune diseases (where checkpoint inhibitor use could trigger life-threatening flares), solid organ transplant recipients on immunosuppression, or patients whose oncologists determine the risk-benefit calculation favors chemotherapy. Some oncologists also use platinum-pemetrexed as a first-line option for selected patients with excellent performance status and epithelioid histology, though this approach is no longer designated as the preferred standard.

Second-line treatment options are limited for mesothelioma patients who progress after first-line immunotherapy. Vinorelbine, gemcitabine, and clinical trial participation are among the options typically considered. Patients who received first-line chemotherapy and subsequently progress may be candidates for nivolumab plus ipilimumab as a second-line regimen, though efficacy data in the second-line immunotherapy-naive setting is more limited than the first-line CheckMate 743 data.

For patients seeking the most current treatment guidance, the mesothelioma lawyers and advocates near you can connect you with specialized oncology centers with experience managing the full spectrum of mesothelioma treatment decisions. Our team works with oncology teams regularly and can help you ask the right questions about whether subcutaneous Opdivo or other immunotherapy options are appropriate for your specific diagnosis and stage.

What Should Mesothelioma Patients Ask Their Oncologist About Subcutaneous Opdivo?

Patients currently receiving IV nivolumab or newly diagnosed patients considering first-line immunotherapy should have an informed conversation with their oncologist about the subcutaneous formulation. Key questions to raise include:

Is subcutaneous Opdivo available at this institution? Not all cancer centers have immediately transitioned to the subcutaneous formulation — pharmacy stocking decisions and nursing protocol updates take time to implement. Confirming availability at the patient's specific center is the first practical step.

Does my insurance plan cover the subcutaneous formulation? As noted in the FAQ above, coverage may differ between IV and subcutaneous formulations for some plans. The oncology financial counselor can verify coverage and help navigate prior authorization if needed before the patient commits to switching.

Are there any clinical reasons to continue IV administration? For some patients — particularly those receiving other IV drugs on the same treatment day — the efficiency advantage of subcutaneous injection may be reduced if an IV line is already being placed for other agents. In these situations, the oncologist may recommend continuing IV nivolumab for simplicity.

What monitoring is required after subcutaneous injection compared to IV infusion? Post-infusion observation periods for IV nivolumab vary by institution. The subcutaneous formulation's side effect profile and the reduced anaphylaxis risk may affect how long post-injection monitoring is required — a question worth clarifying with the treatment team.

If you have been diagnosed with mesothelioma and want to understand all available treatment options, take our free case assessment to connect with our patient advocacy team. We can also review whether your asbestos exposure history qualifies you for compensation through lawsuits or asbestos trust fund claims — financial resources that can help cover the costs of immunotherapy and ongoing treatment. Explore the veterans benefits resources if you served in the military and were exposed to asbestos through your service.

References

1. Mesothelioma Quick Facts - WikiMesothelioma
2. Understanding Your Diagnosis - WikiMesothelioma
3. CheckMate 743: Nivolumab plus ipilimumab versus chemotherapy for unresectable malignant pleural mesothelioma - PubMed
4. Nivolumab (Opdivo) - NCI Drug Information
5. Mesothelioma Treatment - National Cancer Institute
6. Immune Checkpoint Inhibitors - National Cancer Institute
7. ASCO Clinical Practice Guidelines - Mesothelioma
8. Malignant Mesothelioma - American Cancer Society
9. Mesothelioma - National Cancer Institute
10. Asbestos and Cancer Risk - National Cancer Institute
11. Mesothelioma Clinical Trials - ClinicalTrials.gov
12. Asbestos Exposure - Agency for Toxic Substances and Disease Registry
13. Malignant Pleural Mesothelioma Treatment - American Cancer Society